Jennifer Soung, MD

Jennifer Soung, MD, discusses how convenience and ease of use influence treatment adherence and how a new topical JAK inhibitor could enhance real-world outcomes by simplifying application and improving patient compliance.

Jennifer Soung, MD, discusses how ruxolitinib cream, if approved for use in ages 2–11, could become a valuable addition to the treatment landscape for pediatric atopic dermatitis by offering a non-steroidal option for managing inflammation and symptoms.

Jennifer Soung, MD, discusses how having more nonsteroidal options for long-term atopic dermatitis management is crucial, especially for younger children, to minimize potential side effects and support safer, sustained treatment.

Jennifer Soung, MD, discusses how the biggest frustrations parents express about current treatment options for their children with AD, including limited effectiveness, side effects, and the lack of long-term solutions.

Jennifer Soung, MD, discusses how pediatric atopic dermatitis (AD) burdens entire families through sleep disruption and emotional toll. Parents seek effective nonsteroidal options beyond current treatments. Convenient topical Janus kinase (JAK) inhibitors could improve adherence and outcomes.

Experts describe roflumilast patient selection for plaque psoriasis treatment.

Linda Stein Gold, MD, and Jennifer Soung, MD, discuss real world experience of using roflumilast for plaque psoriasis therapy.

Jennifer Soung, MD, review long term data for tapinarof for the treatment of plaque psoriasis.

Experts in plaque psoriasis provide an overview of the itch response and tolerability profile of tapinarof.

Linda Stein Gold, MD, reviews phase III data for the topical agent tapinarof for the treatment of plaque psoriasis.

Linda Stein Gold, MD, and Jennifer Soung, MD, provides an overview of the safety profile and topical vehicle of roflumilast for the treatment of plaque psoriasis.

Linda Stein Gold, MD, discusses the itch response of roflumilast for the treatment for plaque psoriasis.

Experts in plaque psoriasis discuss the primary endpoint data responses of roflumilast in the DERMIS-1/DERMIS-2 trials.

Jennifer Soung, MD, provides an overview of the phase III trials, DERMIS-1/DERMIS-2, in which roflumilast was used to treat plaque psoriasis

Linda Stein Gold, MD, and Jennifer Soung, MD, provide an overview of the different, evidence-based topical strategies for treating plaque psoriasis.